A quick note about where we all stand in regards to the Obamacare healthcare crisis that is upon us:
The House of Representatives moved quickly to pass legislation to repeal the President’s Health Care Reform measures but for breast cancer patients, repeal might not come soon enough.
Breast cancer patients are among the initial victims of the ObamaCare mindset where cost of treatment trumps the effectiveness of treatment. Thanks to the Food and Drug Administration (FDA) the life-extending drug Avastin may no longer be an option for breast cancer patients – despite evidence of its effectiveness and testimony of women—and their doctors– who believe they survive solely because of the drug.
The FDA seems intent on “de-lableing” the drug – a move that would allow insurance companies and Medicare to deny coverage for the drug. Even though the FDA is not charged with considering the cost of a drug when determining its availability, it is apparent they did. Jean Grem of the University of Nebraska explained her anti-Avastin vote by observing, “We aren’t supposed to talk about cost, but that’s another issue."
♦DiggIt! ♦Add to del.icio.us ♦Add to Technorati Faves ♦ Facebook